ScreenerHero
PBHPrestige Consumer Healthcare Inc.
NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · prestigebrands.com
50.05USD-3.16%Mkt Cap: 2.45B $P/E: 14.48

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and interna…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap2.45B $
Enterprise Value4.37B $
Revenue (TTM)1.10B $
Gross Profit595.58M $
Net Income (TTM)190.30M $
Revenue/Share23.04 USD
Last Price50.05 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees890
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)14.48
P/E (Forward)9.94
PEG1.58
EV/EBITDA13.44
EV/Revenue3.96
P/S2.17
P/B1.25
EPS (TTM)3.49
EPS (Forward)5.08
52W Range
42.6226% of range71.07
52W High71.07 USD
52W Low42.62 USD
Profitability
Gross Margin54.71%
Oper. Margin20.83%
EBITDA Margin29.45%
Profit Margin17.48%
ROE10.08%
ROA5.45%
Growth
Revenue Growth6.50%
Earnings Growth-35.80%
Cash Flow & Leverage
Operating CF257.63M $
CapEx (TTM)11.18M $
FCF Margin13.38%
FCF Yield6.04%
Net Debt1.98B $
Net Debt/EBITDA6.08
Balance Sheet
Debt/Equity0.55
Current Ratio3.23
Quick Ratio1.80
Book Value/Sh40.46 USD
Cash/Share1.881 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 27, 2013
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)67.80 USD
Upside (mean)+35.5%
Target Range55.00 USD – 75.00 USD
$55.00+35.5% to mean$75.00
# Analysts5
Ownership
Shares Out.47.37M
Float46.70M
Insiders1.41%
Institutions116.33%
Short Interest
Short Ratio8.0d
Short % Float9.73%
Short % Out.8.06%
Shares Short3.82M
Short (prev mo.)3.21M
Technical
SMA 5049.64 (+0.8%)
SMA 20057.25 (-12.6%)
Beta0.33
S&P 52W Chg18.16%
Avg Vol (30d)420.88K
Avg Vol (10d)530.17K
Technical Indicators
RSI (14)52.2
MACD0.5935
MACD Signal0.8654
MACD Hist.-0.2720
BB Upper54.94 USD
BB Middle51.58 USD
BB Lower48.22 USD
BB Width13.03%
ATR (14)1.950 USD
Vol Ratio (20d)0.61x